Achieve Life Sciences (ACHV) Operating Expenses (2010 - 2026)
Achieve Life Sciences (ACHV) posted Operating Expenses of $10.5 million for Q1 2026, down 28.97% on a QoQ basis from $14.7 million in Q4 2025, and down 18.85% year-over-year from $12.9 million in Q1 2025.
Achieve Life Sciences (ACHV) Operating Expenses (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Operating Expenses history runs 17 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- Quarterly Operating Expenses fell 18.85% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.4 million (up 14.07% YoY) and the FY2025 annual result came in at $54.9 million, up 40.47% from the prior year.
- Operating Expenses was $10.5 million for Q1 2026 at Achieve Life Sciences, down from $14.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $14.7 million in Q4 2025 and bottomed at $4.4 million in Q4 2023.
- A 5-year average of $10.1 million and a median of $10.5 million in 2026 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses tumbled 59.62% — and 2024, when it soared 177.93%.
- Achieve Life Sciences' Operating Expenses stood at $10.9 million in 2022, then slumped by 59.62% to $4.4 million in 2023, then surged by 177.93% to $12.2 million in 2024, then increased by 20.84% to $14.7 million in 2025, then fell by 28.97% to $10.5 million in 2026.
- Business Quant data shows ACHV's Operating Expenses at $10.5 million in Q1 2026, $14.7 million in Q4 2025, and $14.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.10 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -919.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 445.22 Mn |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | 10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.46 Mn |
| Dec 31, 2025 | 14.73 Mn |
| Sep 30, 2025 | 14.69 Mn |
| Jun 30, 2025 | 12.56 Mn |
| Mar 31, 2025 | 12.89 Mn |
| Dec 31, 2024 | 12.19 Mn |
| Sep 30, 2024 | 12.47 Mn |
| Jun 30, 2024 | 8.43 Mn |
| Mar 31, 2024 | 5.98 Mn |
| Dec 31, 2023 | 4.39 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Jun 30, 2023 | 7.71 Mn |
| Mar 31, 2023 | 8.58 Mn |
| Dec 31, 2022 | 10.86 Mn |
| Sep 30, 2022 | 12.64 Mn |
| Jun 30, 2022 | 10.07 Mn |
| Mar 31, 2022 | 7.23 Mn |
| Dec 31, 2021 | 7.12 Mn |
| Sep 30, 2021 | 6.69 Mn |
| Jun 30, 2021 | 11.30 Mn |